Online inquiry

IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9915MR)

This product GTTS-WQ9915MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ9915MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7673MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ8884MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ9988MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ4872MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ10507MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY3002813
GTTS-WQ6953MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ8395MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ8980MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ILV-094
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW